benserazide has been researched along with Dysphagia in 3 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The bioavailability of levodopa-benserazide in a standard capsule and a new dispersible tablet was compared in Parkinsonian patients, with (n = 8) and without (n = 8) swallowing difficulties." | 6.66 | Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia. ( Bayer, AJ; Day, JJ; Finucane, P; Pathy, MS, 1988) |
| "The bioavailability of levodopa-benserazide in a standard capsule and a new dispersible tablet was compared in Parkinsonian patients, with (n = 8) and without (n = 8) swallowing difficulties." | 2.66 | Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia. ( Bayer, AJ; Day, JJ; Finucane, P; Pathy, MS, 1988) |
| "Dysphagia is a frequent and potentially serious complication of Parkinson's disease (PD)." | 1.30 | Swallowing difficulty in Parkinson's disease. ( Chiang, JH; Fuh, JL; Lee, RC; Lin, CH; Liu, HC; Wang, PN; Wang, SJ, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fonda, D | 1 |
| Schwarz, J | 1 |
| Clinnick, S | 1 |
| Fuh, JL | 1 |
| Lee, RC | 1 |
| Wang, SJ | 1 |
| Lin, CH | 1 |
| Wang, PN | 1 |
| Chiang, JH | 1 |
| Liu, HC | 1 |
| Bayer, AJ | 1 |
| Day, JJ | 1 |
| Finucane, P | 1 |
| Pathy, MS | 1 |
1 trial available for benserazide and Dysphagia
| Article | Year |
|---|---|
Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia.
Topics: Aged; Aged, 80 and over; Benserazide; Biological Availability; Capsules; Consumer Behavior; Deglutit | 1988 |
2 other studies available for benserazide and Dysphagia
| Article | Year |
|---|---|
Parkinsonian medication one hour before meals improves symptomatic swallowing: a case study.
Topics: Administration, Oral; Aged; Benserazide; Bromocriptine; Deglutition; Deglutition Disorders; Drug Adm | 1995 |
Swallowing difficulty in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Barium Sulfate; Benserazide; Contrast Media; D | 1997 |